# Mounjaro vs. Zepbound: same molecule, two different labels

> Mounjaro and Zepbound are both tirzepatide from Eli Lilly — the same active molecule with different FDA-approved uses. What that means for indications, insurance, and pharmacy substitution, explained.

**Evidence grade:** Established (rung 1 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-07-07 · **Source page:** https://thepeptideera.com/evidence/mounjaro-vs-zepbound

## Short answer
Mounjaro and Zepbound are the same active molecule — tirzepatide, made by Eli Lilly — sold under two brand names with different FDA-approved uses. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Because the approved use differs, insurance often treats them very differently, even though the drug inside is the same.

## Key takeaways
- Same molecule: both Mounjaro and Zepbound are tirzepatide, a GIP/GLP-1 dual receptor agonist made by Eli Lilly.
- Different labels: Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
- The approved use — not the ingredient — is what usually drives insurance coverage, especially under Medicare's rules for weight-loss versus diabetes drugs.
- They are separate, non-substitutable products: a pharmacist cannot swap one brand for the other, and any decision about which is appropriate belongs with a prescriber.
- Both carry the same boxed warning about thyroid C-cell tumors seen in rats and the same core safety profile — including the same contraindication in people with a personal or family history of medullary thyroid cancer or MEN 2 — because the drug is identical.

## Safety essentials worth knowing

These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority.

- **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician.
- **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception.
- **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
- **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment.
- **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician.
- **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery).

Mounjaro and Zepbound are the same drug wearing two different name tags. Both are **tirzepatide**, both are made by **Eli Lilly**, and the molecule inside the pen is identical. What differs is the label on the box — the specific use the FDA has approved each brand for. That single distinction is why the two are priced, prescribed, and covered by insurance in very different ways, and it is the source of most of the confusion around them.

This page explains that difference. It contains no doses, no titration schedules, and no guidance on which product anyone should use or how to obtain either — those are decisions for a clinician who knows your history.

## Are Mounjaro and Zepbound the same drug?

Chemically, yes. Both are tirzepatide, a **dual agonist** that activates two gut-hormone receptors at once: the GLP-1 receptor and the GIP receptor. Both are manufactured by Eli Lilly. Both carry the same boxed warning (thyroid C-cell tumors seen in rats) and the same core safety profile — including the same contraindication in people with a personal or family history of medullary thyroid cancer or MEN 2 — because pharmacologically they are the same compound.

What is *not* the same is the **FDA-approved indication** — the use each brand is officially licensed and studied for:

| | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide |
| Maker | Eli Lilly | Eli Lilly |
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 + GIP dual agonist |
| Type 2 diabetes | Yes — to improve blood-sugar control, alongside diet and exercise | Not an approved indication |
| Chronic weight management | Not an approved indication | Yes — obesity, or overweight plus a weight-related condition |
| Obstructive sleep apnea | Not an approved indication | Yes — moderate-to-severe OSA in adults with obesity (FDA, Dec 2024) |

This is a well-established, label-level fact rather than a matter of interpretation, which is why this page's evidence grade is *established*: the difference between the two brands is defined by the FDA prescribing information itself, not by any study we are weighing.

Mounjaro's approved job is glycemic control in adults and — following a December 2025 label update — children aged 10 and older with type 2 diabetes (it is not approved for weight management at any age). Zepbound's approved jobs are reducing and maintaining body-weight reduction in adults with obesity (or overweight plus a weight-related condition), and treating moderate-to-severe obstructive sleep apnea in adults with obesity — an approval it received in December 2024, making tirzepatide the first medication the FDA cleared for OSA. Indications can expand over time; the labels are the authoritative source.

## Can one be substituted for the other at the pharmacy?

No. Even though the molecule is identical, Mounjaro and Zepbound are **separate, individually approved products** with their own packaging, their own labels, and their own approved uses. A pharmacist cannot dispense one brand in place of the other the way a generic can be swapped for a brand — they are not designated as interchangeable. If a prescription says Zepbound, the pharmacy fills Zepbound.

That matters because the two are not freely swappable in practice, and any decision to use one product versus the other — including whether the diabetes brand or the weight-management brand is the right fit — is a prescribing decision made by a clinician, not a shortcut a reader should try to engineer. "Same molecule" does not mean "same product, freely exchangeable."

## Why does insurance treat them so differently?

This is where the label difference stops being a technicality and starts costing money.

In the United States, **Medicare Part D is statutorily prohibited from covering drugs prescribed for weight loss**. That prohibition is written into the law, not chosen by individual plans. The practical result: a GLP-1 medicine prescribed for **type 2 diabetes** (or another Medicare-covered condition) can be covered through the standard Part D benefit, while the *same* class of medicine prescribed purely for **weight loss** generally is not.

Because Mounjaro's approved use is diabetes and Zepbound's headline approved use is weight management, the two brands can land on opposite sides of that line even though the drug is identical. Private commercial insurers set their own rules, but many mirror the same logic — covering the diabetes indication more readily than the weight-management one, or requiring different prior-authorization criteria for each.

Two nuances are worth naming honestly:

- Zepbound also carries an approved indication for **obstructive sleep apnea**, which is a Medicare-covered medical condition — so coverage for that specific use is not identical to coverage for weight loss alone. Exactly how a given plan handles it varies.
- Medicare launched a **temporary GLP-1 demonstration** (the "GLP-1 Bridge"), running July 1, 2026 through December 31, 2027, that gives eligible Part D beneficiaries access to certain weight-reduction GLP-1s — including a Zepbound formulation — for a $50 monthly copay, operating *outside* the standard Part D benefit (the copay doesn't count toward the deductible or out-of-pocket cap). It began as a 2026-only program and was extended into 2027; it is still a short-term demonstration, not a permanent change to what Part D covers, so what happens after it ends is unsettled.

Coverage rules shift frequently and differ by plan, employer, and country. The reliable move is to check your specific plan's current formulary rather than assume the two brands are covered the same way.

## Pens, vials, and how they come packaged

A common assumption is that one brand is "the pen" and the other is "the vial." That is no longer a clean distinction. According to the current prescribing information, **both** Mounjaro and Zepbound are available as single-dose prefilled autoinjector pens, as single-dose vials, and as single-patient-use KwikPen devices. The presentation formats have largely converged.

What still differs is the label the box carries and the approved use behind it — not, in most cases, the physical form of the injection. This page does not cover how to prepare, measure, or administer either product; those are steps that belong to a prescription and a clinician's instructions, never to a general reference.

## What "same molecule, different product" really means

Tirzepatide sold as Mounjaro and tirzepatide sold as Zepbound come from the same manufacturer, the same approved supply chain, and the same molecule — so within Lilly's approved products, the compound really is the same. The difference is regulatory: which use each brand is licensed, studied, and labeled for.

That is a very different situation from the **grey market**, where "tirzepatide" sold as an unapproved compounded preparation or a research chemical may share only the *name*. There, the same molecule label offers no guarantee of the same sterility, dose accuracy, purity, or accountability. The Mounjaro-versus-Zepbound comparison is a story about two legitimate, FDA-approved products; it should not be read as reassurance about anything sold outside that approved chain.

## Frequently asked questions

**Is Zepbound just Mounjaro for weight loss?**
Essentially, yes — it is the same molecule (tirzepatide) from the same maker, approved and labeled for weight management and sleep apnea rather than for diabetes. But it is a separate, individually approved product, not simply Mounjaro relabeled by a pharmacist, and the two are not interchangeable at the counter.

**Will they work the same way in the body?**
The active drug is identical, so the underlying pharmacology is the same. Individual response and tolerability still vary from person to person, and any comparison of results between indications should come from a clinician, not from assuming the brand name changes the biology.

**Why is one covered by my insurance and the other isn't?**
Coverage usually tracks the **approved use**, not the molecule. Drugs prescribed for diabetes are covered more readily than the same drugs prescribed for weight loss — most sharply under Medicare, which is legally barred from covering weight-loss drugs. Check your specific plan's formulary, because the rules differ and change often.

**Can I ask to switch from one to the other?**
Whether to use the diabetes-labeled or the weight-management-labeled product is a clinical and coverage decision, not a self-service swap. It is a conversation to have with your prescriber, who can weigh your diagnosis, your insurance, and your history.

**Are compounded or non-prescription "tirzepatide" versions the same as either brand?**
No. The identity established here applies to Lilly's two approved, brand-name products. A product sold outside the approved chain may share the name without sharing the quality, sterility, dose accuracy, or safety accountability of the approved medicines.

## Questions to ask a clinician

- Given my diagnosis — diabetes, obesity, sleep apnea, or a combination — which approved indication actually applies to me?
- How does my insurance treat the diabetes brand versus the weight-management brand, and does that change what's realistic for me?
- If coverage or cost pushes toward one brand, does that create any medical trade-off I should understand?
- What side effects should I expect early, and how would we manage them?
- Is a temporary or demonstration coverage program relevant to my situation, and what happens when it ends?

## Red flags / when to seek care

These are prescription medicines that require medical supervision. The points below are educational, not a substitute for your clinician or emergency services.

- **Severe, persistent abdominal pain**, especially radiating to the back and with vomiting — a possible sign of pancreatitis; seek urgent care.
- **Upper-right abdominal pain, fever, or yellowing of the skin or eyes** — possible gallbladder disease.
- **Signs of dehydration** from prolonged vomiting or diarrhea, or an inability to keep fluids down.
- **Swelling of the face, lips, or throat, or trouble breathing** — a possible severe allergic reaction and a medical emergency.
- Any seller or site offering to supply "the same tirzepatide" without a prescribing clinician, or promising to bypass insurance rules by relabeling one product as the other, is a reason to step back. The comparison that keeps you safe is the one made with someone who knows your history.

## Sources (5)
1. MOUNJARO (tirzepatide) injection — FDA Prescribing Information (DailyMed) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 [LABEL]
2. ZEPBOUND (tirzepatide) injection — FDA Prescribing Information (DailyMed) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b [LABEL]
3. FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound, Dec 2024) — https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea [NEWS]
4. Medicare GLP-1 Bridge — CMS (demonstration runs July 1, 2026 through December 31, 2027; $50 monthly copay; operates outside the Part D benefit) — https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge [GUIDELINE]
5. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (KFF, 2026) — Bridge extended through end of 2027 (originally Dec 31, 2026) — https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid [REVIEW]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.